<DOC>
	<DOCNO>NCT01780935</DOCNO>
	<brief_summary>This study evaluate compare two individualized ranibizumab treatment regimens patient neovascular ( wet ) AMD aim achieve maintain maximum visual function benefit , aim avoid unnecessary intravitreal injection . The result use generate recommendation functional anatomical monitoring disease time treatment administration patient neovascular AMD . In context , study investigate utility optical coherence tomography ( OCT ) aid retreatment decision ranibizumab .</brief_summary>
	<brief_title>Efficacy Safety Two Treatment Regimens 0.5 mg Ranibizumab Intravitreal Injections Guided Functional and/or Anatomical Criteria , Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>During course study , use optical coherence tomography ( OCT ) -guided therapy become standard care accept health authority ophthalmology community treatment neovascular ( wet ) age-related macular degeneration ( nAMD ) , Novartis decide 08-Oct-2014 early termination study . Therefore 12-month cutoff date reach related analysis perform .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment predominantly due neovascular agerelated macular degeneration AMD Active , newly diagnose , untreated CNV due AMD CNV involve center retina A qualify vision score study entry Stroke myocardial infarction le 3 Months prior study entry Active injection inflammation either eye time study entry</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>